Satellos Secures $57.2M Financing, Nasdaq Listing and Advances Two Phase 2 Trials
Satellos secured US$57.2 million in equity financing and commenced Nasdaq trading on Feb. 6, extending cash runway through 2027. The company initiated two Phase 2 trials of SAT-3247—BASECAMP pediatric dosing began Feb. 12 with top-line results expected Q4 2026, and TRAILHEAD adults demonstrated improved grip strength over 9‒13 months.
1. Financing and Nasdaq Listing
Satellos completed a US$57.2 million equity financing on Feb. 9 and began trading on the Nasdaq Global Market on Feb. 6, 2026, strengthening its balance sheet with cash runway expected through 2027.
2. BASECAMP Phase 2 Trial Setup
BASECAMP (CL-201) is a global, randomized, placebo-controlled Phase 2 study in 51 ambulatory boys aged 7 to under 10 with Duchenne muscular dystrophy. First participant dosing occurred Feb. 12 following U.S. FDA and global regulatory clearances; enrollment is projected to finish in Q3 2026 with top-line results due Q4 2026.
3. TRAILHEAD Interim Results
TRAILHEAD (LT-001) is a 12-month, open-label Phase 2 study re-enrolling four adult participants from a prior 28-day trial (CL-101). Interim data through 56 days in TRAILHEAD (84 days combined) show maintained or improved handgrip strength and stability or gains in elbow and shoulder strength, with greater benefits in participants having higher baseline muscle mass.
4. Biomarker Validation and Preclinical Data
Satellos reported proteomic analyses from CL-101 showing reductions in established muscle degeneration biomarkers and confirmed a Regenerative Index biomarker for quantifying muscle regeneration. In preclinical FLEX DUX4 models of FSHD, 12-week SAT-3247 dosing significantly enhanced muscle strength, supporting potential expansion beyond Duchenne.